drug · protein
ficerafusp alfa
Phase 3updated 5mo agoby $BCAX Bicara Therapeutics Inc.🔗 ChEMBL
Phase 3community read0 votes
Protein drug with a maximum clinical stage of Phase 2 3, with 1 investigational indication.
all catalysts(0)
nothing on the calendar yet
Trials studying ficerafusp alfa
- phase3FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
- phase2Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)
- phase2Phase II Study of Ficerafusp Alfa in Combination With Nivolumab in Patients With Platinum-refractory Head and Neck Squamous Cell Carcinoma
- phase2Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC
News(2)
- No ‘Sunday scaries’: Claire Mazumdar on building Bicara—and knowing when to hand over the reinsStrange and bittersweet. That’s how Claire Mazumdar describes her plan to step down from the top spot at Bicara, a biotech she helped form, and head out on parental leave before transitioning into…biospace · 5d ago
- Chutes & Ladders—Former Legend CEO lands at K2Just weeks after Legend Biotech announced the departure of its CEO, Ying Huang, K2 Therapeutics has announced that Wang will now lead the startup, which was founded in 2024 with a $50 million seed…fiercebiotech · 1mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that